BMI and outcomes in melanoma: more evidence for the obesity paradox
A partir de données de six cohortes portant sur 1 918 patients atteints d'un mélanome métastatique traité par immunothérapie, chimiothérapie ou thérapie ciblée entre 2006 et 2016, cette étude rétrospective analyse l'association entre l'indice de masse corporelle et la survie, en fonction des traitements reçus
The association between increased body-mass index (BMI) and the risk of developing and dying from cancer has been recognised across a broad range of tumour types.1,2 The magnitude of this association is so great that in the USA obesity is considered to be the major preventable cause of cancer.3 However, data regarding the effect of obesity on the outcomes of patients undergoing cancer treatment is less clear. Several observational studies in different tumour types have shown that a moderately increased BMI (compared with an optimal BMI of 22·5 kg/m2) is associated with improved outcomes both around the time of treatment and in later years of follow-up for several cancers.
The Lancet Oncology , commentaire, 2017